FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to production of expression vector comprising (a) C68 nucleotide sequence and (b) multi-antigenic DNA construct, which codes for immunogenic polypeptides of prostate-associated antigens (RAA), which can be used in medicine. Expression vector C68 is obtained recombinantly, which is used as part of a pharmaceutical composition to elicit an immune response to RAA.
EFFECT: invention allows to increase the effectiveness of treatment of prostate cancer in humans.
24 cl, 13 dwg, 15 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| HUMANIZED ANTI-PSMA ANTIBODIES | 2019 |
|
RU2794450C2 |
| NGF ANTAGONISTS FOR MEDICAL USE | 2020 |
|
RU2829812C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
